These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33299862)

  • 1. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
    Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
    Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
    Kim NY; Pyo JS
    Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.
    Wu S; Wu D; Pan Y; Liu H; Shao Z; Wang M
    Pathol Res Pract; 2019 Feb; 215(2):292-301. PubMed ID: 30527357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
    Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
    Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.
    Wang X; Zhao H; Lv L; Bao L; Wang X; Han S
    Sci Rep; 2016 Jan; 6():19239. PubMed ID: 26754405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
    Wang M; Li P; Wan R; Liu X
    Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer.
    Tu Z; Chen X; Tian T; Chen G; Huang M
    Aging (Albany NY); 2021 Feb; 13(5):7397-7415. PubMed ID: 33658396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis.
    Gao Z; Shi R; Yuan K; Wang Y
    Tumour Biol; 2016 Nov; 37(11):14979-14987. PubMed ID: 27655285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
    Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
    You Q; Guo H; Xu D
    Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.
    Sun L; Zhou H; Yang Y; Chen J; Wang Y; She M; Li C
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32329507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis.
    Gong K; Zhou H; Liu H; Xie T; Luo Y; Guo H; Chen J; Tan Z; Yang Y; Xie L
    Technol Cancer Res Treat; 2021; 20():15330338211060202. PubMed ID: 34825846
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
    Zheng J; Deng Y; Huang B; Chen X
    Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.